Amphastar Pharmaceuticals, Inc. (AMPH)
23.18
-0.66
(-2.77%)
USD |
NASDAQ |
Sep 04, 16:00
22.90
-0.28
(-1.21%)
After-Hours: 20:00
Amphastar Pharmaceuticals Research and Development Expense (Quarterly) : 18.30M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.30M |
| March 31, 2026 | 22.90M |
| December 31, 2025 | 19.50M |
| September 30, 2025 | 18.73M |
| June 30, 2025 | 16.09M |
| March 31, 2025 | 16.92M |
| December 31, 2024 | 14.86M |
| September 30, 2024 | 17.80M |
| June 30, 2024 | 14.53M |
| March 31, 2024 | 14.23M |
| December 31, 2023 | 17.85M |
| September 30, 2023 | 14.21M |
| June 30, 2023 | 14.46M |
| March 31, 2023 | 17.37M |
| December 31, 2022 | 14.82M |
| September 30, 2022 | 16.04M |
| June 30, 2022 | 20.25M |
| March 31, 2022 | 13.60M |
| December 31, 2021 | 14.72M |
| September 30, 2021 | 8.213M |
| June 30, 2021 | 15.17M |
| March 31, 2021 | 11.83M |
| December 31, 2020 | 15.38M |
| September 30, 2020 | 15.05M |
| June 30, 2020 | 13.69M |
| Date | Value |
|---|---|
| March 31, 2020 | 12.96M |
| December 31, 2019 | 17.50M |
| September 30, 2019 | 16.44M |
| June 30, 2019 | 13.85M |
| March 31, 2019 | 12.48M |
| December 31, 2018 | 15.46M |
| September 30, 2018 | 10.05M |
| June 30, 2018 | 13.83M |
| March 31, 2018 | 12.50M |
| December 31, 2017 | 9.62M |
| September 30, 2017 | 8.947M |
| June 30, 2017 | 9.621M |
| March 31, 2017 | 10.18M |
| December 31, 2016 | 11.44M |
| September 30, 2016 | 8.549M |
| June 30, 2016 | 9.297M |
| March 31, 2016 | 7.173M |
| December 31, 2015 | 7.753M |
| September 30, 2015 | 10.22M |
| June 30, 2015 | 9.733M |
| March 31, 2015 | 5.56M |
| December 31, 2014 | 7.639M |
| September 30, 2014 | 8.585M |
| June 30, 2014 | 5.994M |
| March 31, 2014 | 5.492M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Viatris, Inc. | 245.20M |
| Supernus Pharmaceuticals, Inc. | 29.06M |
| Liquidia Corp. | 16.88M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |